⌘K

Home/Filings/4/0001209191-20-003110

4//SEC Filing

Patterson Matthew R 4

Accession 0001209191-20-003110

CIK 0001628738other

View on SEC.gov Company Profile

Filed

Jan 9, 7:00 PM ET

Accepted

Jan 10, 6:18 PM ET

Size

21.3 KB

Accession

0001209191-20-003110

Insider Transaction Report

Form 4

Period: 2019-12-26

Audentes Therapeutics, Inc.BOLD

Patterson Matthew R

DirectorPresident & CEO

Transactions

Exercise/Conversion
Common Stock
2020-01-08$9.50/sh+11,824$112,328→ 249,792 total
Exercise/Conversion
Common Stock
2020-01-08$15.26/sh+11,666$178,023→ 261,458 total
Exercise/Conversion
Stock Option (right to buy)
2020-01-08−74,297→ 0 total
Exercise: $2.19Exp: 2025-02-04→ Common Stock (74,297 underlying)
Gift
Common Stock
2019-12-26−12,500→ 98,920 total
Exercise/Conversion
Common Stock
2020-01-08$0.78/sh+64,751$50,506→ 163,671 total
Exercise/Conversion
Stock Option (right to buy)
2020-01-08−64,751→ 0 total
Exercise: $0.78Exp: 2023-09-25→ Common Stock (64,751 underlying)
Exercise/Conversion
Common Stock
2020-01-08$2.19/sh+74,297$162,710→ 237,968 total
Exercise/Conversion
Stock Option (right to buy)
2020-01-08−11,824→ 143,569 total
Exercise: $9.50Exp: 2025-12-18→ Common Stock (11,824 underlying)
Exercise/Conversion
Stock Option (right to buy)
2020-01-08−11,666→ 188,334 total
Exercise: $15.26Exp: 2027-01-25→ Common Stock (11,666 underlying)

Holdings

Common Stock
(indirect: By Trust)
171,814

Footnotes (5)

[F1]The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
[F2]The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017.
[F3]The option vested as to 25% of the total shares on February 4, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 4, 2019.
[F4]The option vested as to 6.25% of the total shares quarterly, beginning March 18, 2016, with 100% of the total shares vested and exercisable on December 18, 2019.
[F5]The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Audentes Therapeutics, Inc.

CIK 0001628738

Entity typeother

Related Parties

1

filerCIK 0001401018

Filing Metadata

Form type: 4
Filed: Jan 9, 7:00 PM ET
Accepted: Jan 10, 6:18 PM ET
Size: 21.3 KB

View on SEC.gov